Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Artemisia capillaris aqueous extract (AEAC) is a botanical extract derived from the aerial parts of *Artemisia capillaris* Thunb. or *Artemisia scoparia*. It is a complex mixture of bioactive compounds, including coumarins (such as capillarisin and esculetin), flavonoids, and organic acids. AEAC is primarily studied for its hepatoprotective, anti-inflammatory, and metabolic effects. Its mechanism of action involves the modulation of several signaling pathways, including NF-κB, AMPK, PI3K/AKT, and SREBP-1c, as well as the restoration of Glycine N-methyltransferase (GNMT) activity. Research indicates potential therapeutic applications in non-alcoholic fatty liver disease (NAFLD), obesity, alcoholic liver injury, and vascular dysfunction associated with diabetes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on artemisia capillaris aqueous extract.